Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin vs colistin + carbapenem for XDR Gram-negative bloodstream infection or pneumonia
2017-002110-32Phase 3Completed
- Sponsor
- University of Michigan
- Start
- Apr 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of colistin, imipenem and meropenem in gram-negative bacteremia, Gram-negative pneumonia and bacterial infection due to other gram-negative organisms (2 arms), sponsored by University of Michigan. Primary endpoint: All-cause mortality at 28–30 days. Started Apr 2018; status: completed.
02
Drugs
colistinimipenemmeropenem
03
Conditions
gram-negative bacteremiaGram-negative pneumoniabacterial infection due to other gram-negative organisms
Beyond the preview
Go deeper on 2017-002110-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002110-32.